NYX-2925

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameNYX-2925
Drug Alias NameNYX-2925
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor modulators
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyDiabetic NeuropathiesFibromyalgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAptinyx Inc
China Registration ClassN/A

Develop Information

Active CompaniesAptinyx Inc
Inactive CompaniesN/A
Active IndicationsDiabetic NeuropathiesFibromyalgia
Inactive IndicationsDiabetic peripheral neuropathy

Other Information

ATC CodeN/A
Related LinksN/A